4-(吡啶-2-基)哌啶-4-甲腈 | 767263-33-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-(吡啶-2-基)哌啶-4-甲腈
• 英文名称: 4-(pyridine-2-yl)piperidine-4-carbonitrile
• 英文别名: 4-(pyridin-2-yl)piperidine-4-carbonitrile；4-pyridin-2-ylpiperidine-4-carbonitrile
• CAS: 767263-33-2
• 化学式: C₁₁H₁₃N₃
• mdl: MFCD18071627
• 分子量: 187.244
• InChiKey: VXQVGWZSCZUOKK-UHFFFAOYSA-N

物化性质

• 沸点：
  371.4±42.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  48.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(吡啶-2-基)哌啶-4-甲腈 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 3-[4-(pyridin-2-yl)-4-cyano-piperidin-1-yl]propylamine
  参考文献：
  名称：

  Phenylacetamides as selective α-1A adrenergic receptor antagonists

  摘要：

  A novel class of potent and selective or-la receptor antagonists has been identified. The structures of these antagonists were derived from truncating the 4-aryl dihydropyridine subunit present in known alpha-1a antagonists. The design principles which led to the discovery of substituted phenylacetamides, the synthesis and SAR of key analogues, and the results of select in vitro and in vivo studies are described. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00307-3
• 作为产物：
  描述：

  苄基N-[2-(N-(2-氨基-4-甲氧基-苯基)苯胺基)-2-氧代-乙基]氨基甲酸酯 在 disodium;dihydroxide;hydrochloride 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 4-(吡啶-2-基)哌啶-4-甲腈 作用下， 以 trifluoracetic acid-dichloromethane 为溶剂， 反应 0.67h， 以to afford the desired product 4-pyridin-2-ylpiperidine4-carbonitrile (I-3) as a yellow solid的产率得到4-(吡啶-2-基)哌啶-4-甲腈
  参考文献：
  名称：

  Heteroaryl piperidine glycine transporter inhibitors

  摘要：

  本发明涉及抑制甘氨酸转运体GlyT1的吡啶基、吡啶嗪基、嘧啶基和吡嗪基哌啶化合物，这些化合物在治疗与甘氨酸能或谷氨酸能神经递质失调相关的神经和精神障碍以及涉及甘氨酸转运体GlyT1的疾病中具有用途。

  公开号：

  US07825135B2
• 作为试剂：
  描述：

  苄基N-[2-(N-(2-氨基-4-甲氧基-苯基)苯胺基)-2-氧代-乙基]氨基甲酸酯 在 disodium;dihydroxide;hydrochloride 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 4-(吡啶-2-基)哌啶-4-甲腈 作用下， 以 trifluoracetic acid-dichloromethane 为溶剂， 反应 0.67h， 以to afford the desired product 4-pyridin-2-ylpiperidine4-carbonitrile (I-3) as a yellow solid的产率得到4-(吡啶-2-基)哌啶-4-甲腈
  参考文献：
  名称：

  Heteroaryl Piperidine Glycine Transporter Inhibitors

  摘要：

  本发明涉及抑制甘氨酸转运体GlyT1的吡啶基、吡啉基、嘧啶基和吡嗪基哌啶化合物，其在治疗与甘氨酸能或谷氨酸能神经递质功能障碍相关的神经和精神障碍以及涉及甘氨酸转运体GlyT1的疾病中具有用途。

  公开号：

  US20070254880A1

文献信息

• [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE LA QUINOLIZIDINONE
  申请人：MERCK & CO INC

  公开号：WO2009051715A1

  公开（公告）日：2009-04-23

  The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的螺环哌啶化合物，这些化合物是M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。
• [EN] AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 À BASE D'AMINOBENZOQUINAZOLINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011084371A1

  公开（公告）日：2011-07-14

  The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的氨基苯并喹唑醌酮化合物，其为M1受体阳性变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍等方面有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗M1受体介导的疾病中使用这些化合物和组合物。
• [EN] FLUORO-NAPHTHYL DERIVATIVES<br/>[FR] DÉRIVÉS DE FLUORO-NAPHTYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015110370A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R2 is hydrogen, halogen, lower alkyl, cyano, C4-6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five-or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

  本发明涉及通式化合物，其中R1为C4-6环烷基或C4-6杂环烷基，其可任选地被一个或两个选自羟基或低级烷基的取代基取代；A为苯基、吡啶基或哌啶基；R2为氢、卤素、低级烷基、氰基、C4-6环烷基、低级烷氧基、被卤素取代的低级烷氧基，或为可任选地被低级烷基取代的五元或六元杂芳基；n为1或2；或涉及药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。这些化合物可用于治疗或预防阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍。
• FLOURO-NAPHTHYL DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160326144A1

  公开（公告）日：2016-11-10

  The present invention relates to compounds of formula wherein R 1 is C 4-6 -cycloalkyl or C 4-6 -heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R 2 is hydrogen, halogen, lower alkyl, cyano, C 4-6 -cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five- or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

  本发明涉及通式化合物，其中R1为C4-6环烷基或C4-6杂环烷基，其任选地被一个或两个选自羟基或低级烷基的取代基取代；A为苯基、吡啶基或哌啶基；R2为氢、卤素、低级烷基、氰基、C4-6环烷基、低级烷氧基、被卤素取代的低级烷氧基，或为任选地被低级烷基取代的五元或六元杂芳基；n为1或2；或涉及药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。这些化合物可用于治疗或预防阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍。
• [EN] N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 CONTENANT DES LACTAMES LIÉS À N
  申请人：MERCK SHARP & DOHME

  公开号：WO2012158475A1

  公开（公告）日：2012-11-22

  The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一般式（I）的N-连接内酰胺化合物，这些化合物是M1受体阳性变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。该发明还涉及包括这些化合物的药物组合物，以及在治疗由M1受体介导的疾病中使用这些化合物和组合物。